Airway inflammation in asthma involves complex, interactive, and redundant cascades
mediated by an array of proinflammatory cytokines, including a type 2 (T2) pattern of injury …

Here we review how biomarkers have been used in the design, execution and interpretation
of recent clinical studies of therapeutic candidates targeting cytokine-mediated inflammatory …

Asthma is a chronic inflammatory airway disease associated with type 2 cytokines
interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus …

Asthma is a chronic respiratory disorder canonically associated with type 2 airway
inflammation as characterized by elevated levels of eosinophils, immunoglobulin E, and …

Asthma is a heterogeneous inflammatory disease characterized by airflow obstruction,
wheezing, eosinophilia and neutrophilia of the airways. Identification of distinct inflammatory …

Objective The use of biologics in severe asthma has made substantial strides in disease
management and fostered a personalized medicine approach; however, how, when, and …

Asthma is a chronic inflammatory disorder of the lower airways that results in sustained
coughing and shortness of breath. In addition to greatly affecting quality of life and posing a …

Although airway inflammation is an intrinsic and key feature of asthma, this response varies
in its intensity and translation to clinical characteristics and responsiveness to treatment. The …

Asthma is a common disease with an increasing prevalence worldwide. Up to 10% of these
patients have asthma that is refractory to current therapy. This group have a disproportionate …

Asthma is an inflammatory disease of the airway wall that leads to bronchial hyper-reactivity
and airway obstruction, caused by inflammation, mucus hyper-production and airway wall …